Compare DexCom, Inc. (DXCM) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Li Auto Inc — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.86B), while Li Auto Inc trades at $11.4 (market cap $10.71B). The key difference: DexCom, Inc. is far larger — about 3× Li Auto Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Li Auto Inc for 101 Days on average.
| DXCM | LI | |
|---|---|---|
Market Cap | $31.86B | $10.71B |
Volume | 3,607,070 | 1,781,143 |
Sector | Health | Consumer Cyclical |
52-Week High | $92.34 | $23.61 |
52-Week Low | $54.84 | $10.69 |
Typical Hold Time | 62 Days | 101 Days |
Enterprise Value | $31.32B | $139.58M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
Li Auto (LI) trades at $10.99, near its 52-week low, with a bearish technical signal and recent earnings misses in Q1 and Q2 2026. Revenue declined to $112.31B in 2025, with a net income margin of 1%, while cash flow from operations turned negative. The company faces intense competition in China's EV market, though new model launches like the Li i9 aim to revive growth.
The stock presents a high-risk opportunity, with a consensus price target of $15.18 implying upside, but investors must weigh analyst caution (43.75% buy rating) against execution risks and ongoing cash burn. Near-term performance hinges on delivery recovery and margin improvement amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
